Overview

Reprab Study: PLD + Trabectedin Rechallenge

Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Treatments:
Trabectedin